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Gestational diabetes mellitus (GDM) is a heterogeneous
disorder that complicates 2-3% of all pregnancies in the
world (Sepe et al., 1985; Gabbe, 1986). It is defined as
glucose intolerance with first onset during pregnancy, and
it presents significant perinatal risks such as premature
birth, congenital abnormalities, fetal morbidity and
mortality, and obstetric complications. Gestational diabetes
also increases maternal risk for later development of
manifest diabetes (Gabbe, 1986; Anonymous, 1988). During
normal pregnancy, a gradual deterioration of glucose
tolerance can take place 50 that plasma glucose
concentrations following a glucose load or a meal are higher
than non-pregnancy (Kuhl, 1975; Kuhl et al., 1977). However,
in most pregnant women, plasma glucose stays within normal
ranges and deteriorates in only 2-3% of pregnancies
sufficiently for the development of diabetes (Kuhl et al.,
1984) .
Although glucose intolerance in GDM is usually mild,
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the higher incidence of maternal complications and fetal
perinatal risks make it important to recognize and treat
this condition. As a result, the pathophysiologic background
of GDM must be known. The reason pregnancy is capable of
inducing a temporary diabetic state is still unclear (Kuhl
and Anderson, 1988). One of several explanations is that
nutritional factors may play a role in the development of
GDM (Aharoni et al., 1992).
Chromium is an essential trace mineral for humans and
animals. It functions in maintaining normal glucose
tolerance by increasing insulin efficiency, therefore
reducing the amount of insulin required to control blood
glucose concentration and related processes (Anderson,
1992). Marginal states of chromium nutriture may contribute
to progressive glucose tolerance impairment and increase the
risk of diabetes (Mertz, 1993). There is strong evidence
that glucose intolerance induced by insufficient dietary
chromium could be alleviated by supplemental chromium
(Anderson, 1992). However, not all diabetic patients can
benefit from dietary chromium supplementation (Anderson,
1992). Response to chromium is related to the degree of
glucose intolerance (Anderson, 1989).
studies also reported decreased hair chromium
concentration in the last stage of pregnancy in GDM (Aharoni
et al., 1992), and increased urinary chromium excretion with
advancing pregnancy (Saner, 1981). These findings observed
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in GDM indicate that chromium deficiency may be a possible
factor in the etiology of GDM.
Because diabetes is associated with generalized defects
in connective tissue metabolism, and collagen is the major
protein component of connective tissue (Bornstein and Traub,
1979), abnormalities in collagen metabolism may playa role
in connective tissue alterations in GDM (Spanheimer et al.,
1988). An observed decrease in collagen mass in diabetes may
result from decreased collagen synthesis, increased collagen
degradation, or a combination of these two processes (Lien
et al., 1992).
Hydroxyproline is considered to be a good indicator of
collagen degradation because it is present almost
exclusively in collagen and not reutilized in the synthesis
of collagen (Prockop and Kivirikko, 1967). Of the total
amount of hydroxyproline produced in the body by collagen
catabolism, 90-95% is further broken down, while 5-10%
appears in urine (Prockop, 1964). Because collagen is turned
over continuously, a relatively constant amount of
hydroxyproline is excreted in the urine every day (Berg and
Kerr, 1992). This makes it possible to measure 24 or 12 hour
urinary hydroxyproline excretion as an index of collagen
breakdown.
Moreover, because more than 50% of the total collagen is
present in bone tissue (Klein and Curtiss, 1964) and bone
collagen has a higher turnover rate than collagen elsewhere
in the body, the skeleton is estimated to be the source of
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approximately 70-80% of urinary hydroxyproline (Birkenhager,
1970). Significant relationships have been found between
diabetes and bone hydroxyproline concentration (Locatto et
al., 1990; Ishida et al., 1988). Therefore, in this study we
measured bone hydroxyproline as another important indicator
to evaluate collagen metabolism in GDM. Furthermore, bone
calcium was also measured to evaluate the effect of GDM on
bone composition. In streptozotocin (STZ) -induced diabetic
rats, researchers found a significant reduction in bone
calcium concentration as bone mass was decreased in diabetes
(Locatto et al., 1990).
Significance of the research
A few studies investigating the relationships between
chromium nutri tion and GDM have been conducted, but they
were mostly conducted on human subj ects and were hard to
control. Likewise, a great deal of research has been
performed to evaluate the altered collagen degradation in
diabetes using hydroxyproline as an indicator, but these
studies were conducted using non-pregnant diabetic models.
Currently, there is no research evaluating the
relationship between chromium depletion and the
hydroxyproline concentration in GDM using a rat model. Our
study was designed to measure bone and urinary




chromium depletion on collagen metabolism in STZ-induced
gestational diabetic rats.
Objectives
The following research objectives were developed:
1. To determine if chromium
urinary hydroxyproline excretion
pregnant rats and control rats.
2. To determine if chromium depletion would alter bone
hydroxyproline concentration in STZ-induced diabetic
pregnant rats and control rats.
3. To determine if chromium depletion would alter bone
calcium concentration in STZ-induced diabetic pregnant rats
and control rats.
Hypotheses
The following research hypotheses were developed:
1. There will be no statistically significant effects of
chromium depletion or of STZ-induced diabetes on urinary
hydroxyproline excretion in pregnant rats.
2. Chromium depletion or STZ-induced diabetes will not
statistically alter bone hydroxyproline concentration in
pregnant rats.
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3. Bone calcium concentration will not be statistically
altered by chromium depletion or STZ-induced diabetes in
pregnant rats.
Limitations
This study was designed to evaluate the effect of
chromium depletion on GDM using a rat model, so the data
obtained can not be extrapolated directly to humans. In
addition, the sample size in this study was small and may
not accurately reflect alterations in hydroxyproline
concentration in GDM. However, our findings about the
relationship between chromium and hydroxyproline
concentration in GDM utilizing an animal model may help
direct human research. Further studies are suggested in this
area using larger numbers of animals.
CHAPTER II
LITERATURE REVIEW
Etiology of gestational diabetes mellitus
Gestational diabetes mellitus (GDM) presents significant
risks for both the fetus and the mother (Gabbe, 1986;
Anonymous, 1988). Maternal complications of GDM include
pregnancy-induced or chronic hypertension, pyelonephritis,
preterm labor, hydramnios, abnormalities of labor, birth
trauma, and increased risk of later development of manifest
diabetes (Goldman et al., 1991). Perinatal risks include
higher incidence of macrosomia, hypoglycemia,
hyperbilirubinemia, hypocalcemia, polycythemia, and
congenital abnormalities (Schwartz, 1990). Hypoglycemia,
which may cause neurological damage, and polycythemia, which
may cause both neurological damage and renal vein
thrombosis, present the greatest danger. Hypoglycemia and
polycythemia can be promptly diagnosed and corrected;
however, macrosomia can not be reversed once established.
Macrosomia may cause delayed chronic morbidity to the




in later life (Hod et al., 1991). As a result, it is very
important to recognize the etiology of GDM and to be able to
treat and prevent this condition.
Why pregnancy is capable of inducing GDM is still
unknown (Kuhl and Anderson, 1988). Glucose tolerance
deteriorates during pregnancy in spite of steadily
increasing plasma insulin concentration (Kuhl et al., 1985).
This indicates that pregnancy may induce insulin resistance.
Women with GDM who received an oral glucose load had
significantly increased insulin concentration during
pregnancy versus postpartum (Kuhl and Holst, 1976; Hornnes
et al., 1981). A similar response was observed in pregnant
women with normal glucose tolerance (NGT) (Kuhl, 1975).
However, in women with GDM, peak plasma insulin
concentrations occurred later than in pregnant women with
NGT (Kuhl and Holst, 1976). Moreover, the first-phase
insulin response and the insulin secretory capacity in women
with GDM were significantly reduced compared to that of
pregnant women with NGT (Kuhl, 1991). All these data support
the hypothesis that pregnancy-induced insulin resistance may
be responsible for the development of GDM.
However, the cause of insulin resistance in pregnancy is
still unclear. It may be induced by changes in insulin-
receptor binding, postreceptor changes (Pedersen, 1984), or
cellular effects of high plasma pregnancy-associated
hormones or free cortisol (Kuhl, 1991). The effects are a
reduction in whole-body insulin sensitivity to about one-
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third of non-pregnant state. Most pregnant women are able to
have a compensatory increase in both basal and nutrient-
stimulated insulin secretions to counteract pregnancy-
induced insulin resistance, but approimately 2-3% may not
possess the capability to produce a sufficiently large
increase in insulin secretion, resul ting in glucose
intolerance (Kuhl, 1991). These are probably the women who
develop GDM.
The role of chromium nutrition in the etiology of GDM
One assumption for pregnancy-induced insulin resistance
is that nutritional factors such as chromium deficiency, may
play a role in its development (Aharoni et al., 1992).
Chromium is an essential trace mineral in humans and
animals, which has a role in glucose homeostasis (Morris et
al., 1993). Chromium has been proposed to function in
maintaining normal glucose tolerance by forming a glucose-
tolerance factor (GTF), which acts as a cofactor with
insulin in all insulin-dependent systems, and thus increases
insulin efficiency (Mertz, 1976; Hambidge, 1974). As a
result, with sufficient chromium, lower insulin is required
to control blood glucose and related processes (Anderson,
1992). On the other hand, with inadequate chromium, glucose
tolerance is impaired, increasing the risk of diabetes
(Mertz, 1969).
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There is strong evidence that glucose intolerance
induced by insufficient dietary chromium can be alleviated
with supplemental chromium (Anderson, 1992). Morris et ale
(1985) found plasma chromium concentrations were
significantly lower in diabetes (60% of normal) and chromium
excretion was elevated (nearly three times) compared to
normal healthy subjects. Fasting glucose, circulating
insulin, insulin binding, circulating glucagon, and ~-cell
sensitivi ty were improved wi th increased chromium status
(Anderson, 1989). Hypoglycemic symptoms including glucose
values, insulin binding, and insulin receptor numbers were
also improved in hypoglycemic patients following chromium
supplementation (Anderson et al., 1987).
However, not all diabetic patients demonstrated
beneficial effects of supplemental chromium. One explanation
is that response to supplemental chromium may be related to
diabetic stages, form and amount of supplemental chromium,
duration of supplementation, and chromium status (Anderson,
1992). For example, some diabetic patients may lose the
ability to convert inorganic chromium to a physiologically
active form and therefore are dependent upon active chromium
complexes from foods (Toepfer et al., 1973). When sufficient
chromium was consumed in a usable form, insulin requirement
was low due to the insulin-potentiating activity of
biologically active chromium complexes (Anderson 1992). In
addition, studies have found that diabetic mice also lost
the ability to convert inorganic chromium to a usable form.
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Diabetic mice supplemented with inorganic chromium showed no
effect, while biologically active chromium supplementation
reduced glucose to normal concentrations (Tuman et al.,
1978) •
Chromium defeciency is one of the causes of glucose
intolerance in diabetes. Because chromium is not a
therapeutic agent, only patients whose glucose intolerance
is related to insufficient dietary chromium could benefit
from improved chromium nutrition (Anderson, 1992).
Pregnancy may lead to chromium deficiency and thus
increase the risk of developing GDM (Saner, 1981). Hair
chromium concentration of women with GDM significantly
decreased in the later stage of pregnancy; this decrease was
not observed in non-diabetic pregnant women (Aharoni et al.,
1992). Moreover, another study found urinary chromium
excretion increased significantly wi th advancing pregnancy
(Saner, 1981). The decreased hair chromium concentration and
the increased urinary chromium excretion during later
pregnancy, as well as the evidence of impairment of glucose
tolerance during pregnancy, suggest that chromium deficiency
might be an etiological factor in GDM.
The abnormalities of collagen metabolism in diabetes
The nature of connective tissue defect in diabetes
Diabetes is associated with generalized defects in
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connective tissue metabolism, such as poor wound healing
(Goodson and Hunt, 1979), decreased bone mass and formation
rate (Goodman and Hori, 1984), and vascular basement
membrane thickening (Raskin et al., 1975). Because collagen
is the most abundant protein in vertebrate animals and the
major protein component of connective tissues (Bornstein and
Traub, 1979), abnormalities in collagen metabolism may play
a role in the widespread nature of connective tissue
alterations in GDM.
Collagen mass is decreased in diabetes. A net loss of
skin and wound healing collagen mass (Goodson and Hunt,
1977) as well as reduced bone mass and decreased bone
formation rate have been observed in diabetic patients
(Goodson and Hunt, 1979). Loss of interstitial collagen in
connective tissues may result from decreased collagen
synthesis (Spanheimer et al., 1988), enhanced catabolism of
newly synthesized collagen (Schneir et al., 1982), or a
combination of these two processes.
The decrease of collagen synthesis
Collagen synthesis may be decreased in diabetes.
Spanheimer and colleagues (1988) reported that wi thin two
weeks after induction of diabetes with streptozotocin (STZ),
collagen production was significantly reduced 52% and 51% in
bone and cartilage of diabetic rats compared to control
rats.
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The mechanism for this decrease is still unclear. There
is evidence that insulin can increase collagen synthesis by
promoting intracellular accumulation of certain amino acids,
such as L-proline, which is associated with accelerated
collagen synthesis (Wettenhall et al., 1969). One hypothesis
is that insulin insufficiency in diabetes contributes to
decreased collagen synthesis.
The increase of collagen degradation
Diabetes also can increase collagen catabolism. Schneir
and coworkers (1982) found the collagen catabolic process
was enhanced in the skin of STZ-induced diabetic rats by
quantitating the amount of dialyzable [3H]- hydroxyproline
in skin homogenates after short-term [3H]-proline injection.
Twenty-four hours after [3H]-proline injection, 4.5% of
radiolabeled collagen mass in diabetic rats' dried skin
existed as low molecular weight [ 3H] -hydroxyproline-
containing material, in contrast to 1.1% in control rats'
skin. When wet skin was analyzed, 30-40% of the radiolabeled
collagen mass appeared as [3H]-hydroxyproline-containing
material in diabetic rats, and only 10-20% in control rats.
Thus they concluded that intracellular collagen degradation
was accelerated by experimental diabetes.
The mechanism for effects of diabetes on collagen
degradation is not clear. In vitro studies demonstrated that
glucose inhibited fibril formation and subsequent collagen
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cross-linking. Thus, collagen synthesized in a high glucose
environment appears to be less cross-linked and thereby more
susceptible to collagenase digestion (Lien et al., 1992) I
which might explain increased collagen degradation in
diabetes.
Hydroxyproline as an indicator of collagen degradation
Hydroxyproline is related to collagen metabolism
Hydroxyproline is a good indicator of collagen
degradation based on the nature of collagen metabolism.
Collagen is secreted by fibroblasts and osteoblasts
(Birkenhager, 1970). There are three stages in collagen
development (Schneir et ale I 1982) : (1) intracellular
procollagen from proline (2) extracellular tropocollagen
(recently synthesized collagen) and (3) mature collagen
fibers (soluble or insoluble). Collagen contains 33%
glycine, 13% proline, and 9% hydroxyproline (Mavrikakis et
al., 1993). Certain proline residues in collagen are
converted into hydroxyproline by prolyl hydroxylase
(Kivirikko et al., 1989). This hydroxyproline in the
collagen peptide linkages plays a crucial role in collagen
folding, and it can only be hydroxylated from proline,
whereas exogenous hydroxyproline does not appear in collagen
at all. Collagen catabolism is catalyzed by collagenase,
thereafter hydroxyproline is released as a degradative
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product. Of the total amount of hydroxyproline produced in
the body by collagen degradation, 90-95% is further broken
down to carbon dioxide and urea (Birkenhager, 1970), while
5-10% appears in the urine (Prockop, 1964). Urinary
hydroxyproline is derived from soluble as well as insoluble
collagen. Because of the unique character of hydroxyproline,
which is present almost exclusively in collagen and not
reutilized in the synthesis of collagen, the production of
hydroxyproline has been assumed to reflect collagen
catabolism (Prockop and Kivirikko, 1967).
Diabetes may affect collagen catabolism in all three
stages of collagen development (Schneir et al., 1982). The
catabolism of at least the first two stages which are
procollagen and tropocollagen can be quanti tated by
measuring hydroxyproline-containing products (Bienkowski et
al., 1978). In this study we used hydroxyproline as an
indicator to evaluate altered collagen metabolism in
diabetic rats.
Urinary hydroxyproline excretion
Since collagen is turned over continuously, a relatively
constant amount of collagenous peptides containing
hydroxyproline is excreted in the urine every day (Berg and
Kerr, 1992) . In addi tion, further study found the
degradation of newly synthesized collagen was very rapid
(Bienkowski et al., 1978). Approximately 30% of collagen
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synthesized by rabbit lung parenchyma explants was degraded
within 8 minutes after [14C]-proline was added to the
incubation. This was within the time required for synthesis
and less than that required for secretion (Vuust and Piez,
1970; Lane et al., 1971; Dehm and Prockop, 1972). One
explanation for this rapid degradation is that it regulates
the quality of proteins that are synthesized, so that
abnormal molecules are recognized and destroyed (Bradley and
Schimke, 1976; Schimke and Bradley, 1975; Goldberg and Dice,
1974; Goldberg and St.John, 1976). Collagen is a large
protein that is subject to many post-translational
modifications (Bienkowski et al., 1978), as a result, errors
in collagen synthesis can be destructed quickly. This rapid
collagen degradation makes it possible to use 24 or 12 hour
urinary hydroxyproline excretion as an index of collagen
degradation.
There is evidence that urinary hydroxyproline excretion
is increased in diabetes. Mani and Mani (1986) found higher
24 hour hydroxyproline excretion in diabetic patients
particularly in insulin-dependent diabetes. They reported
mean hydroxyproline excretion, expressed on a creatinine
basis, was 34.9 ~g/mg creatinine for insulin-dependent
diabetes, and 16.1 ~g/mg creatinine for normals. In another
study using the STZ-induced diabetic rat model (Mavrikakis
et al., 1993), a significant increase in urinary
hydroxyproline excretion was also found after diabetes was
induced as compared to baseline concentrations. Mean 24 hour
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hydroxyproline concentrations before diabetes induction was
33. 5±1. 6 J.lg/mg creatinine, and from the 4th to 87th day
after induction, the values were increased from 83.0±4.9
~g/mg creatinine to 115.0±8.2 ~g/mg creatinine. This
increase may be due to an acceleration in collagen breakdown
rate in diabetes.
Bone hydroxyproline and calcium concentration
Because more than 50% of total collagen store is present
in bone tissue (Klein and Curtiss, 1964) and bone collagen
has on the average a higher turnover rate than the collagen
elsewhere in the body, such as skin and tendon, the skeleton
is the source of about 70-80% of the urinary hydroxyproline
(Birkenhager, 1970). Additionally, because collagen mass
decreases in diabetes, hydroxyproline concentration, which
is considered as an index of collagen mass, also is thought
to decrease in the bones of diabetics. Ishida and coworkers
(1988) and Takeshita and colleagues (1993) reported that
hydroxyproline per femur was significantly reduced in STZ-
induced diabetic rats. Values obtained in the first study
were lO.S±O.3 mg/femur in diabetic rats compared to 14.4±O.3
mg/femur in controls. In addition, Locatto et ale (1990)
found femur hydroxyproline concentration was directly
correlated to plasma insulin concentration, since insulin
insufficiency was observed to cause decreased bone
hydroxyproline concentration. Therefore, in this study we
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measured bone hydroxyproline to evaluate abnormal collagen
metabolism in GDM.
Bone calcium content can reflect the influence of GDM on
bone composition. Studies found a significant reduction of
bone calcium mass in STZ-induced diabetic rats (Verhaeghe et
al., 1990). Calcium was decreased by 22% and 17% in the
tibia and femur, and by 24% in the four lumbar vertebrae.
Bone strength was also decreased in diabetic rats. This is
probably because of the effect of insulin insufficiency on
bone mass in diabetes. Insulin is important for bone cell
function, since insulin receptors were found to be present
in osteoblastic cells (Levy et al., 1986). Also, insulin
promoted growth in an osteoblast-like cell line (Hickman and
McElduff, 1989). Thus insulin insufficiency in diabetes
resul ted in decreased osteoblast number. This osteoblast
dysfunction remained evident and decreased bone mineral
apposition and bone strength (Verhaeghe et al., 1990).
Another suggestion is that there is a deficiency of
insulin-like growth factor-I (IGF-I) in diabetes. IGF-I
stimulates osteoblast replication and bone matrix synthesis
(Canalis, 1980; Hock et al., 1988). Receptors for IGF-I were
also found in osteoblasts (Bennett et al., 1984). The
deficiency of this growth factor in diabetes was considered
partly responsible for decreased osteoblast recruitment and
function, and may thereby contribute to reduced bone mass,
bone mineral apposition, and bone strength in diabetes
(Verhaeghe et al., 1990).
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As a result, altered collagen metabolism in GDM can be
assessed by measuring urinary and bone hydroxyproline
concentrations to evaluate the effect of chromium depletion
on GDM. In this study, we used STZ-induced diabetic pregnant
rats as an animal model of GDM, which could develop chronic




Forty-eight weanling female Sprague Dawley rats were
used in this study. The study was a 2x2 factorial design
with STZ and dietary chromium as variables (see appendix A) .
Initially, all rats were maintained on low chromium diet
(see appendix B) before they became pregnant. Rats were
weighed weekly until they were between 200 to 250 g and were
between 56-72 days old. Then each female rat was housed with
a male rat. Vaginal plugs were checked every day after
breeding, as a pregnancy indicator. If no vaginal plug was
observed on the fourth day, we assumed that the rat was
pregnant. On the day when a vaginal plug was observed or on
the fourth day, the rat was treated with STZ or placebo, and
the +Cr or -Cr diet was started. STZ was injected
intravenously to the rats in STZ treatment groups via the
tail vein. The dose of STZ was 35 mg/kg body weight for the
first five rats in each group. Afterwards, it was changed to
25 mg/kg body weight due to an observed tendency for
abortion to occur in pregnant rats treated with 35 mg STZ/kg
20
21
body weight. Because urine collection began after the STZ
dose was changed, we considered the urinary hydroxyproline
concentration before breeding would not be altered by the
different STZ dosage. Citrate buffer was inj ected to the
rats in placebo groups.
Twenty days later, the animals were necropsied. Animals
were not fasted before autopsy. Blood samples were collected
by cardiac puncture, placed on ice, and centrifuged. Plasma
was separated immediately and stored at -20°C until assayed.
Blood glucose was measured by the glucose oxidase method and
insulin was determined by radioimmunoassay. Insulin and
glucose assays were performed by Maria Spicer.
Because urine collection began about one month after the
beginning of the experiment, some of the rats had already
been bred or necropsied. Fifteen animals were available for
analyzing urine hydroxyproline before mating and 31 after
STZ or placebo treatment. Forty animals were available for
bone and blood analysis. Non-pregnant rats and those who
delivered or died before necropsy were eliminated from this
study.
Determination of urinary hydroxyproline concentration
Urine samples were collected on the day before mating,
and 17 days after STZ or placebo (-STZ) treatment. Rats were
kept in metabolic cages designed for separation of urine and
feces at room temperature from 9 PM to 9 AM. They were on a
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12 hour light and dark cycle from 7 AM to 7 PM. Animals were
fed water and food during the 12 hour collection period.
Urine was collected in a container which was kept cool in an
ice holder. Urine samples were stored in polypropylene tubes
at -20°C until hydroxyproline was assayed about three months
later.
Urinary hydroxyproline concentration was determined
using the Bergman and Loxley method (1970). This method has
been confirmed successful to measure hydroxyproline in urine
hydrolysates in spite of the presence of interfering
materials, because internal standards are used (see appendix
C). After urine was hydrolyzed, a lithium hydroxide solution
was used to neutralize the hydrolysates in order to
eliminate possible salt precipitation. Then oxidant solution
and Ehrlich's reagent were added. Oxidant solution was added
after Ehrlich's reagent in the blank. Chloramine-T in the
oxidant solution was inactivated by the perchloric acid
which was in the Ehrlich's reagent, thus any color
development was due to materials other than hydroxyproline.
As a result, a desirable blank for urine could be obtained.
The absorbance was measured at 562 nm in a 1xl cm cuvette.
Determination of bone hydroxyproline concentration
Bone samples were collected on the day rats were
necropsied. Femur and tibia were dissected from adhering
connective tissue and muscle, and then stored at -20°C in
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plastic bags for about five months. On the day of analyses,
the length and weight of the right femur bones were
measured. Then a 2 rom thick cross-section was cut from the
mid-diaphysis of the bones and weighed (Shaw et al., 1987).
These cross-sections were broken into small pieces and
placed into polypropylene tubes with 0.5 ml of 6 M
hydrochloric acid added. The tubes were then sealed and put
in an oven at 105°C for 24 hours. After acid hydrolysis,
they were cooled to room temperature and dried in a vacuum.
Acid residues were redissolved in distilled water for
hydroxyproline assay. The Bergman and Loxley method (1970)
was also used for bone hydroxyproline determination.
Determination of bone calcium concentration
Bone calcium concentration was measured using the method
developed by Hill et ale (1986), which includes a combination
of wet and dry ashing. Tibial bones were used for this
assay. After bone wet weights were measured, the bones were
dried for 48 hours at 100°C to obtain dry weights. Bones
were ashed in a muffle furnace at 375°C for 48 hours. After
cooling, deionized water, nitric acid (concentrated, double
distilled, GFS Chemicals, Inc. Columbus, OH), and Ul trex
hydrogen peroxide (30%, ultrapure, Baker, Inc. Phillipsburg,
NJ) were added to each tube in a heating block. Hydrogen
peroxide was added every two hours, four times each day.
After several days of wet ashing, samples were again dry
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ashed and wet ashed several times until all black carbon
particles were digested and bone powder became completely
whi te. Concentrated ni tric acid and deionized water were
added again to dissolve the bone powder. Samples were
vortexed every hour until all residue was dissolved. Then
o.1% lanthenum chloride in O. 5% nitric acid was added to
prevent the interference of some elements such as aluminum,
beryllium, phosphorus, silicon, titanium, and zirconium,
which can give rise to stable oxysalts, and thereby reduce
calcium sensitivity. Bone calcium concentration was
determined by flame atomic absorption spectrometry at 422.7
nm.
statistical analysis
All data were expressed as means ± SEM. Statistical
analysis of the data was performed on SAS using analysis of
variance and correlation analysis. Log transformations were
performed on plasma insulin and glucose to correct for non-




The effect of chromium and diabetic state on urinary
hydroxyproline excretion in pregnant rats
Urine volume and urinary hydroxyproline before and after
treatment were available from 15 rats. The total number of
urine samples obtained after treatment was 31. Plasma
insulin, glucose, bone hydroxyproline and calcium
concentrations were available from 40 rats.
On the day before breeding, there were no differences in
urine volume (Table 1) among groups. In addition, there were
no significant differences in the urinary hydroxyproline
excretion per uni t body weight among the groups. Because
these data were obtained before any treatment was
administrated, the results were desired to avoid
experimental error.
No significant differences were observed between urine
volume measured the day before breeding and 17 days after
treatment within the same rats among groups (Table 1). This
was probably due to the small sample size, as there were
only three to five rats which had paired urine samples in
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TABLE I
URINARY HYDROXYPROLINE EXCRETION AND URINE VOLUME IN PREGNANT RATS WITH STZ OR
PLACEBO TREATMENT AND WITH CHROMIUM ADEQUATE OR DEPLETION DIETSt
Trt N Urine Vol (ml/12hr) Hyp (Jlg/g body Wt)
1 1 11 2 A3 1 1 11 2 6 3
-STZ-CR 3 8±1 22±17 13±17 O.44±O.O4 O.49±0.09 0.O6±O.O6
-STZ+CR 5 7±1 11±14 3±14 0.43±0.03 0.37±0.08 -0.O6±O.O6
+STZ-CR 3 7±1 20±17 14±17 0.4S±O.04 0.96±0.11 O.47±0.O8
+STZ+CR 4 8±1 44±15 36±15 0.47±0.04 0.82±0.08 O.35±0.O6
P Values
STZ 0.71 0.34 0.33 0.52 0.0005 0.0001
CR 0.80 0.69 0.71 0.82 0.16 0.11
STZ*CR 0.36 0.30 0.34 0.78 0.94 0.99
t Values are means ± SEM.
1 Data were obtained on the day before breeding.
2 Data were obtained 17 days after treatment.





Within the same animals, differences between urinary
hydroxyproline excretion per unit body weight before and
after streptozotocin (STZ) or placebo treatment were greater
in GDM rats than control rats (p=O. 0001 i Table 1). This
finding indicated that after the induction of diabetes by
STZ, hydroxyproline excretion in urine was significantly
increased compared with that before STZ administration.
However, differences in hydroxyproline concentrations before
and after STZ or placebo treatment were not significantly
affected (p=O.11) by dietary chromium.
Twenty days after treatment, plasma insulin
concentration decreased in gestational diabetes mellitus
(GDM) rats compared to control rats (p=O.001; Table 2), but
no difference was observed between the chromium adequate
(+Cr) diet groups and chromium depletion (-Cr) diet groups.
Moreover, plasma glucose concentrations measured on the same
day increased in GDM rats compared to control rats
(p=0.003), but differences between +Cr and -Cr diet groups
were not significant. These observations indicated strong
evidence of the induction of diabetes in pregnant rats after




be explained by the
symptoms observed in
Urine volume measured 17 days
increased in GDM rats compared to
Table 2). This finding could
physiological changes and clinical
TABLE II
URINARY HYDROXYPROLINE CONCENTRATION AND PLASMA INSULIN AND GLUCOSE
IN PREGNANT RATS WITH STZ OR PLACEBO TREATMENT AND WITH
CHROMIUM ADEQUATE OR DEPLETION DIETSl
Trt Urine Vol2 Hyp 2 Insulin 3 Glucose 3
(ml/12hr) (Jlg/g body wt) (ng/ml) (rng/dl)
N=31 N=31 N=40 N=40
-STZ-CR 19±10 O.46±O.O7 4.32±O.77 341.8±59.0
-STZ+CR 10± 9 O.38±O.O7 2.19±O.73 292.0±S6.0
+STZ-CR 34±12 1.22±O.10 0.70±O.73 471.2±S6.0
+STZ+CR 43±11 O.88±O.07 O.84±0.77 519.6±S9.0
P Values
STZ 0.03 0.0001 0.0001 0.003
CR 0.99 0.01 0.32 0.56
STZ*CR 0.38 0.12 0.33 0.46
1 Values are means ± SEM.
2 Data were obtained 17 days after treatment.




diabetes. However, an effect of chromium on urine volume was
not observed.
Urinary hydroxyproline excretion per uni t body weight
after STZ or placebo treatment was increased in GDM rats
compared to placebo-treated pregnant rats (p=O.OOOl; Table
2) . In addition, there was an increase in urinary
hydroxyproline excretion in the rats fed a chromium
depletion diet compared with those fed a chromium adequate
diet (p=O.Ol). The urinary hydroxyproline concentration was
increased from 0.88±0.07 ~g/12hr/g body weight to 1.22±O.10
~g/12hr/g body weight in GDM rats fed the chromium depletion
diet, and it was increased from O.38±O.07 ~g/12hr/g body
weight to O. 4 6±0. 07 J.1g/ 12hr/ g body weight in control rats
fed the chromium depletion diet.
Urinary hydroxyproline concentration measured 17 days
after treatment was positively correlated with the glucose
concentration measured observed 20 days after treatment in
pregnant rats (r=O.66; Figure 1). This also indicated that
diabetes was related to increased urinary hydroxyproline
excretion in pregnant rats.
Hydroxyproline is a good indicator of collagen breakdown
and is thereby considered to reflect the connective tissue
alterations in diabetes state. In this study, 12 hour
urinary hydroxyproline excretion per uni t body weight was
significantly higher in the pregnant rats after STZ
treatment compared to placebo treatment. This is probably
because of increased collagen breakdown in STZ-induced
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1 Values were obtained 17 days after treatment.
2 Values were obtained 20 days after treatment.
Figure 1. Correlation between Urinary Hydroxyproline
and Plasma Glucose in Pregnant Rats
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diabetic pregnant rats. In diabetes, collagen tends to be
less cross-linked and more susceptible to collagenase
digestion because high glucose environment can inhibit
fibril formation and subsequent collagen cross-linking.
Thereafter, urinary hydroxyproline excretion was increased
as a product of collagen breakdown (Mavrikakis et al.,
1993). Mavrikakis and coworkers reported 24 hour urinary
hydroxyproline concentration in rats was 33. 5±!. 59 IJ,g/mg
creatinine before STZ treatment, and increased from 83.0±4.9
IJ,g/mg creatinine to 115.0±8.2 ~g/mg creatinine from the 4th
day to 87th day after the induction of diabetes by STZ. Our
findings were in agreement wi th their report. The
correlation between urinary hydroxyproline concentrations
and plasma glucose concentration observed in this study also
supports this hypothesis.
A function of chromium is maintaining normal glucose
tolerance by increasing insulin efficiency; thus, chromium
deficiency is considered a possible etiological factor of
GDM. Dietary chromium supplementation may have beneficial
effects on GDM. We assumed urinary hydroxyproline excretion
would be increased in the rats fed a chromium depletion
diet. In this study, urinary hydroxyproline excretion per
unit body weight was increased in GDM rats and control rats
fed a chromium depletion diet compared with those fed a
chromium adequate diet. One explanation is that chromium
depletion leads to glucose intolerance, and collagen
synthesized in a high glucose environment tends to be more
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easily catabolized, resulting in increased urinary
hydroxyproline excretion. Dietary chromium supplementation
may alleviate some symptoms associated with decreased
collagen quality in GDM.
However, the difference in hydroxyproline concentration
before and after treatment between +Cr diet groups and -Cr
diet groups was not significant. This may be due to our
small sample size, as the number of the rats who had paired
urine samples was only three to five in each group.
We also found a significant difference in urinary
hydroxyproline concentration between GDM rats fed an
adequate chromium diet and placebo-treated rats fed a
chromium depletion diet (p=O.002). This indicated that
chromium depletion in pregnant rats did not develop as
severe diabetes as that in GDM rats fed a chromium adequate
diet.
The effect of chromium and diabetic state on bone
hydroxyproline and calcium concentration
in pregnant rats
Body weight obtained on the day of autopsy was not
significantly different between GDM rats and control rats
(Table 3), nor between the rats fed chromium adequate or
chromium depletion diets. When weight gain from the day
before breeding to the day of autopsy was compared, GDM rats
gained less weight than control rats (p=O.02). A significant
TABLE III
BODY WEIGHT AND BONE LENGTH AND WEIGHT IN PREGNANT RATS WITH STZ OR PLACEBO
TREATMENT AND WITH CHROMIUM ADEQUATE OR DEPLETION DIETSt
Trt N Body wt Femur Length Femur wt
(g) (nun) wet (g)
1 1 11 2 A3
-STZ-CR 10 271±17 382±22 111±11 39.3±0.6 0.63±0.O3
-STZ+CR 10 253±17 343±22 90±11 39.7±0.6 0.SS±O.03
+STZ-CR 10 279±17 338±27* SO±13 39.9±O.7 O.60±0.O4
+STZ+CR 10 267±17 313±25* 61±12 39.S±0.6 O.62±O.O3
P Values
STZ 0.52 0.14 0.02 0.53 0.88
CR 0.38 0.18 0.09 0.86 0.64
STZ*CR 0.S4 0.76 0.92 0.74 0.42
t Values are means ± SEM.
1 Data were obtained on the day before breeding.
2 Data were obtained 20 days after treatment.
3 Values are the differences between I and II.




effect on weight gain due to chromium depletion was not
observed (p=0.09).
The weight and length of femoral bones were not
different between STZ and placebo treatment groups (Table
3). Chromium depletion also had no effect on bone weight or
length.
Bone hydroxyproline concentration per milligram of femur
was decreased in GDM rats compared to control rats (p=0.02;
Table 4), but no difference was found between +Cr and -Cr
diet groups. Total hydroxyproline per femur was not affected
by any treatment.
Calcium concentration of tibial bones was not different
among groups (Table 4). Likewise, the moisture of tibial
bones in GDM rats and control rats was not different, nor
did chromium status affect tibial moisture.
As shown in Figue 2, bone hydroxyproline concentration
(~g/mg femur) was positively correlated with plasma insulin
concentration measured 20 days after treatment (r=O. 55) .
This indicates an adverse effect of diabetes on bone
hydroxyproline concentration in pregnant rats.
Our finding agreed with the study by Ishida and
colleagues (1988). They found bone hydroxyproline per femur
was 10.S±O.3 rng in diabetic rats and 14.4±O.3 mg in control
rats. Locatto and coworkers (1992) also concluded that
insulin deficiency in diabetes was correlated to the
decrease of bone hydroxyproline content in alloxan-treated
diabetic rats.
TABLE IV
BONE HYDROXYPROLINE AND CALCIUM CONCENTRATIONS IN PREGNANT RATS WITH STZ OR
PLACEBO TREATMENT AND WITH CHROMIUM ADEQUATE OR DEPLETION DIETSl
Trt N Hyp2 Moisture 3 Ca 3
Ilg/mg femur mg/femur % mg/g
-STZ-CR 10 24.32±1.70 14.67±1.48 28.59±O.86 230.5±1.9
-STZ+CR 10 23.33±1.70 13.52±1.40 27.32±O.86 230.7±1.9
+STZ-CR 10 19.58±1.80 12.44±1.71 28.58±O.86 231.4±1.9
+STZ+CR 10 19.19±1.70 11.76±1.48 27.72±0.86 228.6±1.9
P Values
STZ 0.02 0.20 0.82 0.75
CR 0.69 0.55 0.23 0.50
STZ*CR 0.86 0.88 0.81 0.44
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1 Values were obtained 20 days after treatment.
Figure 2. Correlation between Bone Hydroxyproline
and Plasma Insulin in Pregnant Rats
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Bone hydroxyproline concentration per milligram of femur
was decreased in GDM rats compared to control rats. As
discussed, collagen mass is reduced in diabetes because of
enhanced collagen degradation or decreased collagen
synthesis, thus hydroxyproline concentration in collagen is
reduced consequently. Because bone contains more than 50% of
total body collagen stores, bone hydroxyproline is
considered to be decreased in diabetes (Locatto et al.,
1992). The positive correlation between bone hydroxyproline
concentration and plasma insulin concentration in this study
supports this hypothesis. However, bone calcium
concentration was not affected by diabetes in this study.
Chromium depletion can lead to glucose intolerance and
is speculated to be a possible etiological factor of GDM
(Aharoni et al., 1992). When comparing bone hydroxyproline
concentrations in GDM and control rats with chromium
adequate or depletion diets, we did not find any difference
due to dietary chromium. Bone calcium concentration was not
affected by chromium depletion either. This may be because
of the small sample size, the short duration of this study
(20 days), or experimental error. Nevertheless, the effect
of chromium depletion on bone hydroxyproline or calcium
concentration in GDM can not be clarified in this study.
..
CHAPTER V
SUMMARY, HYPOTHESIS TESTING AND RECOMMENDATIONS
Summary
The purpose of this study was to evaluate the effect of
chromium depletion on collagen metabolism in gestational
diabetes mellitus (GDM) by measuring bone and urinary
hydroxyproline concentration in streptozotocin (STZ)-induced
diabetic pregnant rats.
Chromium functions to maintain normal glucose tolerance
by increasing insulin efficiency. In chromium deficiency,
glucose tolerance is impaired, increasing the risk of
developing diabetes. Therefore, chromium depletion is
speculated to be a possible etiological factor in the
development of GDM.
Because diabetes is associated with generalized defects
in connective tissue metabolism, and collagen is the major
protein component of connective tissues, collagen metabolism
may be al tered in diabetes (Bornstein and Traub, 1979).
Hydroxyproline is a degradative product of collagen and is a
good indicator of collagen breakdown. In this study, urinary
excretion of hydroxyproline was measured as an indicator of
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collagen degradation in GDM. Furthermore, bone
hydroxyproline and bone calcium concentrations reflect
reduced collagen mass in diabetes. These parameters were
also used as indicators to evaluate the effect of chromium
depletion on GDM.
Plasma insulin was significantly decreased in GDM rats
compared to control rats, while plasma glucose was
significantly increased in GDM rats compared to control
rats. However, chromium depletion did not affect plasma
insulin or glucose concentrations in GDM or control rats.
Urinary excretion of hydroxyproline per unit body weight
was increased in GDM rats compared with placebo-treated
pregnant rats. In addition, hydroxyproline concentration was
increased in rats fed a chromium depletion diet compared
with those fed a chromium adequate diet in GDM and control
rats.
Bone hydroxyproline concentration per milligram of femur
was decreased in GDM rats compared to control rats. No
difference in bone hydroxyproline concentration between +Cr
and -Cr diet groups was observed in this study. Bone calcium
concentration was not different among STZ and placebo
treatment groups or +CR and -CR diet groups.
Urinary hydroxyproline concentrations measured 17 days
after treatment were positively correlated with the plasma
glucose concentrations measured 20 days after treatment in
the pregnant rats. A positive correlation was also found
between bone hydroxyproline concentrations and plasma
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insulin concentrations measured 20 days after treatment in
the pregnant rats. These findings indicated that diabetic
state was related to increased urinary hydroxyproline
concentration, and had an adverse effect on the bone
hydroxyproline concentration in pregnant rats.
Overall, we found a significant increase in urinary
hydroxyproline excretion and a decrease in bone
hydroxyproline concentration in STZ-induced diabetic
pregnant rats. This is probably because of the reduced bone
collagen mass as well as the increased collagen breakdown in
GDM rats. Urinary hydroxyproline excretion was elevated as a
result of increased collagen breakdown.
Moreover, we found a significant increase in urinary
hydroxyproline concentration in rats fed a chromium
depletion diet. Because chromium functions to maintain
normal glucose tolerance, chromium depletion may lead to
glucose intolerance and increased collagen breakdown in
pregnant rats. However, no difference was found in the bone
hydroxyproline concentrations with chromium depletion or
adequate diet. Bone calcium concentration was not affected
either. This may be due to the limited sample size or to the
short duration of this experiment.
Hypothesis testing




1. Urinary hydroxyproline concentrations were increased
in STZ-induced diabetic pregnant rats compared to control
rats wi th chromium adequate or depletion diets. Chromium
depletion increased urinary hydroxyproline concentrations in
pregnant rats. As a result, hypothesis one was rejected.
2. Bone hydroxyproline concentrations were decreased in
STZ-induced diabetic pregnant rats compared to control rats
with chromium adequate or depletion diet, but chromium
depletion did not have an effect on bone hydroxyproline
concentrations. As a resul t, hypothesis two was partially
rejected.
3. Bone calcium concentration was not
diabetes or chromium depletion in pregnant
result, hypothesis three was not rejected.
Recommendations
To confirm the effect of chromium depletion on the
al tered hydroxyproline concentration and abnormal collagen
metabolism in GDM, further studies are suggested. In our
study, the sample size in each treatment group was not
large, especially for urine analyses. Because we started
collecting urine samples one month after the begining of the
experiment, some of the rats were no longer available,
especially for ini tial urine collection. In addi tion, the
duration of diabetes induced by STZ in this experiment may
not be long enough to reflect the effect of chromium
depletion on bone
study in this area
recommended.
hydroxyproline
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THE DETERMINATION OF HYDROXYPROLINE IN URINE
Reagents
Oxidant solution
Buffer - 57 g of sodium acetate, 37. 5 g of trisodium
citrate, 5.5 g of citric acid and 385 ml of isopropanol are
made up to 1 litre with distilled water. It is stable
indefinitely.
7% aqueous chloramine-T - 0.7 g chloramine-T are added
with distilled water to 10 ml solution. This is made up
daily.
Mix one part of 7% aqueous chloramine-T and four parts
of buffer to oxidant solution just before each set of
determination.
Ehrlich's reagent
17. 6 g of p-dirnethylaminobenzaldehyde are dissolved in
40.8 g of 60% perchloric acid on the day of use and are made
up to 100 ml with isopropanol just before use.
55
standard solutions
One mg of hydroxyproline is mixed with 100 ml
isopropanol to solution. Then it is diluted to different
concentrations.
Standard I - 0.01 ~g/ml
Standard II - 0.5 ~g/ml
Standard III - 1.0 ~g/ml
Procedures
1. On the first day, mix 2.5 ml of urine and 2.5 ml of 12 N
hydrochloric acid in the marked polypropylene tubes.
2. Put two tubes per beaker in an oven. Heat overnight at
lOO-105°C (at least 16 hours).
3. On the next day, preheat waterbath first. Then turn off
oven and let the tubes cool down to about 40°C.
4. Weigh out 0.5 g amount of lithium hydroxide for each
tube.
5. Put one drop phenolphthalien solution and add weighed
lithium hydroxide to each sample. Cover and mix until
solids are in solution.
6. If solution is still clear, add saturated lithium
hydroxide drop by drop while shaking tube. stop when
color starts to appear. Then add dilute hydrochloric
acid so that solution is clear again.
7. Add distilled water to solution to make it 7.5 mI.
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Centrifuge for 10 minutes at medium speed.
8. Transfer 0.5 ml of the neutralized hydrolysates into 6
test tubes, which are marked as a, b (for duplicate
samples), 1, 2, 3 (for standards), B (for blank).
9. Add 1 ml isopropanol to tube a, b, and B.
10. Add 1 ml standard I to tube 1, 1 ml standard II to tube
2, and 1 ml standard III to tube 3.
11. Add 0.5 ml oxidant solution to tube a, b, 1, 2, 3, but
not to blank. Vortex for 3 seconds each, then wait for 4
minutes (±l minute) .
12. Add 1 ml Ehrlich's reagent to all tubes (a, b, 1, 2, 3,
and B) .
13. Add 0.5 ml oxidant solution to blank. Vortex for 10
seconds each.
14. Set the tubes in 60°C waterbath for 21 minutes. Then let
them sit for one hour at room temprature.
15. Warm up spectrophotometry 15 minutes before the end of
the hour, set at 562 nm.
16. Read all tubes (a, b, 1, 2, 3, and B) at one time.
VITA
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